Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 219 clinical trials
Featured trial
CALGB 40903: A Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women with Estrogen Receptor Positive Ductal Carcinoma in Situ (DCIS)

CALGB 40903: A Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women with Estrogen Receptor Positive Ductal Carcinoma in Situ (DCIS)

  • 344 views
  • 08 Nov, 2020
  • 1 location
Featured trial
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Investigational Product in Patients With Systemic Lupus Erythematosus (SLE)

A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Investigational Product in Patients With Systemic Lupus Erythematosus (SLE)

  • 974 views
  • 08 Nov, 2020
  • 1 location
Study of CG0070 Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin (BOND-003)

(BCG) unresponsive disease, with either carcinoma in situ with or without Ta/T1 disease

  • 0 views
  • 10 Jul, 2022
  • 51 locations
NORTH-REG Dwell-Time Study

Previous studies show that the majority NMIBC patients experience side effects to BCG and therefore terminate the instillations before completing all planned instillations. This will increase their risk of recurrence and potential cystectomy. The purpose of this study is to investigate if NMIBC patients who experience severe side effects to …

  • 0 views
  • 04 Oct, 2022
  • 11 locations
  • 0 views
  • 19 Jun, 2022
  • 7 locations
Breast Cancer Locator Guided vs. Wire Localized Partial Mastectomy for Breast Cancer

breast cancer or ductal carcinoma in situ (DCIS). Subjects will be randomized to breast conserving surgery (BCS) utilizing either the BCL or wire localization (WL) to guide surgery.

  • 0 views
  • 29 Dec, 2021
  • 14 locations
Low Energy Shock Wave Therapy and Non-Muscle Invasive Bladder Cancer

The investigators hypothesize that low energy shock wave therapy (LESW) might induce damage to the tumor tissues of non-muscle invasive bladder cancer (NMIBC), so they could be ablated and detached from the surface. The patients who are suffering from NMIBC will be randomly allocated into two groups: The first group …

  • 0 views
  • 27 Jan, 2021
  • 1 location
Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ

carcinoma in situ (DCIS) patients, the aforementioned two studies included a proportional patients who had young age and negative estrogen receptor (ER) status tumor. Previous studies and our studies

breast cancer
carcinoma in situ
radiotherapy to breast
estrogen receptor
mammogram
  • 18 views
  • 14 Feb, 2022
  • 1 location
Management of Low-risk (Grade I and II) DCIS (LORD)

A substantial number of DCIS lesions will never form a health hazard, particularly if it concerns slow-growing low-risk DCIS (grade I and II). This implies that many women might be unnecessarily going through intensive treatment resulting in a decrease in quality of life and an increase in health care costs, …

breast cancer
estrogen receptor
mammogram
HER2
mastectomy
  • 464 views
  • 04 Jun, 2022
  • 51 locations
Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS (COMET)

is that management of low-risk Ductal Carcinoma in Situ (DCIS) using an AM approach does not yield inferior cancer or quality of life outcomes compared to surgery.

lumpectomy
breast cancer
carcinoma in situ
invasive cancer
mammogram
  • 1343 views
  • 25 Feb, 2022
  • 118 locations